- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 113852-37-2] Cidofovir
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-17438 |
| Brand: | MCE |
| CAS: | 113852-37-2 |
Overview
| MDL | MFCD00866936 |
|---|---|
| Molecular Weight | 279.19 |
| Molecular Formula | C8H14N3O6P |
| SMILES | OC[C@@H](OCP(O)(O)=O)CN1C=CC(N)=NC1=O |
1 Publications Citing Use of MCE
Summary
Cidofovir (GS 0504) is an acyclic monophosphate nucleotide analogue and CMV inhibitor with antiviral activity. Cidofovir inhibits cytomegalovirus (CMV) replication by selectively inhibiting viral DNA polymerase . Cidofovir induces apoptosis and can be used in studies of AIDS cytomegalovirus retinitis, herpes, and cancer [1] [3] . Cidofovir also has anti- orthopoxvirus and anti-variola activities [4] .
In Vitro
Cidofovir (5-100 μM, 72 hours) has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC
50
of 11 μM, and can reduce Crandell-Reese feline kidney cell counts in a dose-dependent manner
[1]
.
Cidofovir (10-1000 μM, 24-120 hours) can reduce cancer cell viability and induces apoptosis
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay [1]
| Cell Line: | Crandell-Reese feline kidney(CRFK) cells |
| Concentration: | 10-100 μM |
| Incubation Time: | 72 hours |
| Result: | Reduced CRFK cells by 9.1%. |
Cell Viability Assay [3]
| Cell Line: | Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells |
| Concentration: | 10-1000 μM |
| Incubation Time: | 24, 48, 72, 96, 120 hours |
| Result: | Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group. |
Apoptosis Analysis [3]
| Cell Line: | FTC-133 cells |
| Concentration: | 100 μM |
| Incubation Time: | 96 hours |
| Result: | Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells. |
In Vivo
Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female weanling BALB/c mice infected with cowpox virus (CPV) [2] |
| Dosage: | 100 mg/kg |
| Administration: | Subcutaneous injection; 3-6 days interval; 21 days |
| Result: |
Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection.
Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00002327 | Gilead Sciences|NIH AIDS Clinical Trials Information Service |
HIV Infections|Condyloma Acuminata
|
Phase 1 | |
| NCT01946009 | Fundacion SEIMC-GESIDA |
HIV
|
September 2013 | Not Applicable |
| NCT00002384 | Gilead Sciences|Anderson Clinical Research|NIH AIDS Clinical Trials Information Service |
Cytomegalovirus Retinitis|HIV Infections
|
Not Applicable | |
| NCT00956176 | M.D. Anderson Cancer Center|Gilead Sciences |
Cystitis|Bladder Diseases
|
Not Applicable | |
| NCT01295645 | M.D. Anderson Cancer Center |
Transplantation Infection
|
March 2011 | Phase 2 |
| NCT00138424 | National Institute of Allergy and Infectious Diseases (NIAID) |
BK Virus (Nephropathy)
|
May 2006 | Phase 1|Phase 2 |
| NCT00002142 | Gilead Sciences|NIH AIDS Clinical Trials Information Service |
Cytomegalovirus Retinitis|HIV Infections
|
Not Applicable | |
| NCT00000142 | Johns Hopkins Bloomberg School of Public Health|Baylor College of Medicine|Johns Hopkins University|Louisiana State University Health Sciences Center in New Orleans|Icahn School of Medicine at Mount Sinai|New Jersey Medical School|NYU Langone Health|Northwestern University|University of California, Los Angeles|University of California, San Diego|University of California, San Francisco|University of Miami|University of North Carolina, Chapel Hill|University of South Florida |
HIV Infections|CMV Cytomegalovirus Retinitis
|
April 1994 | Phase 2|Phase 3 |
| NCT00002116 | Gilead Sciences|NIH AIDS Clinical Trials Information Service |
Herpes Simplex|HIV Infections
|
Phase 1 | |
| NCT02976987 | Brugmann University Hospital |
High Grade Cervical Epithelial Neoplasia (CIN2&addition;)
|
February 2013 | Phase 2 |
| NCT02567149 | University of Minnesota |
Warts
|
June 2016 | Phase 2 |
| NCT02931539 | Shire|Takeda |
Cytomegalovirus (CMV)
|
December 22, 2016 | Phase 3 |
| NCT00002437 | Gilead Sciences|NIH AIDS Clinical Trials Information Service |
Cytomegalovirus Retinitis|HIV Infections
|
Phase 2 | |
| NCT01866397 | Medical University of Vienna|University of Vienna |
Cytomegalovirus Retinitis|Acute Renal Failure
|
March 2002 | Phase 4 |
| NCT00948506 | University of Pennsylvania |
Prevention of Hair Growth
|
July 2009 | Phase 2 |
| NCT00550589 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC |
Anal Cancer|Precancerous Condition
|
September 2007 | Phase 2 |
| NCT00000945 | National Institute of Allergy and Infectious Diseases (NIAID) |
HIV Infections|Leukoencephalopathy, Progressive Multifocal
|
Not Applicable | |
| NCT00004794 | National Center for Research Resources (NCRR)|Northwestern University|Office of Rare Diseases (ORD) |
Cytomegalovirus Retinitis|Acquired Immunodeficiency Syndrome
|
March 1995 | Phase 2 |
| NCT00989443 | Mithra Pharmaceuticals |
Uterine Cervical Neoplasms|Cervix Intraepithelial Neoplasia
|
May 2010 | Phase 1 |
| NCT00000881 | National Institute of Allergy and Infectious Diseases (NIAID) |
Cytomegalovirus Infections|Cytomegalovirus Retinitis|HIV Infections
|
Phase 1 | |
| NCT04055142 | Hospital Universitari Vall d´Hebron Research Institute |
High-grade Anal Intraepithelial Neoplasia
|
September 2019 | Phase 3 |
| NCT00000894 | National Institute of Allergy and Infectious Diseases (NIAID) |
Cytomegalovirus Retinitis|HIV Infections
|
Phase 4 | |
| NCT00002181 | Gilead Sciences|NIH AIDS Clinical Trials Information Service |
Herpes Simplex|HIV Infections
|
Not Applicable | |
| NCT00205374 | University of Wisconsin, Madison |
Recurrent Respiratory Papillomatosis
|
November 1999 | Phase 4 |
| NCT00000143 | Johns Hopkins Bloomberg School of Public Health |
Cytomegalovirus Retinitis|HIV Infections
|
May 1997 | Phase 3 |
| NCT00001126 | National Institute of Allergy and Infectious Diseases (NIAID) |
Papilloma
|
Phase 1 | |
| NCT00000799 | National Institute of Allergy and Infectious Diseases (NIAID)|Gilead Sciences |
Cytomegalovirus Retinitis|HIV Infections
|
Not Applicable | |
| NCT01816646 | M.D. Anderson Cancer Center|Gilead Sciences |
Blood And Marrow Transplantation
|
September 2013 | Phase 1 |
| NCT00019240 | National Cancer Institute (NCI) |
Sarcoma
|
November 1996 | Phase 2 |
| NCT02555800 | Centro de Investigación en. Enfermedades Infecciosas, Mexico |
Recurrent Respiratory Papillomatosis
|
December 2014 | Phase 2 |
| NCT00811408 | Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI) |
Cervical Cancer|Precancerous Condition
|
April 2008 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 3.33 mg/mL ( 11.93 mM ; Need ultrasonic)
DMSO : < 1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble or slightly soluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.5818 mL | 17.9090 mL | 35.8179 mL |
| 5 mM | 0.7164 mL | 3.5818 mL | 7.1636 mL |
| 10 mM | 0.3582 mL | 1.7909 mL | 3.5818 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 4.55 mg/mL (16.30 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
References
- [1] David J Maggs, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403.
- [2] M Bray, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis. 2000 Jan;181(1):10-9.
- [3] Simona Catalani, et al. Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir. Toxicol In Vitro. 2017 Jun;41:49-55.
- [4] Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.